pharmaceuticals

IMPACT FACTOR 4.6 | Indexed in: PubMed | CITESCORE 4.7

an Open Access Journal by MDPI

Lung Injury and Repair

Guest Editor:

Dr. Nektarios Barabutis
College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA

Deadline for manuscript submissions:
closed (31 January 2022)

Message from the Guest Editor

Dear Colleagues,

We are pleased to announce the launch of the "Lung Injury and Repair" Special Issue of *Pharmaceuticals*. This Special Issue will emphasize the most recent advances in the field of pulmonary biology and therapeutics, to provide the research and medical community with the most up-to-date information in the corresponding fields. We welcome the submission of manuscripts (research articles, reviews) investigating the etiologies of lung disease, as well as the development of medical countermeasures against lung injury (direct and indirect). Such injuries include (but are not limited to) the following: acute lung injury, acute respiratory distress syndrome, aspiration, sepsis, trauma, SARS-CoV-2-inflicted ARDS, pneumonia, fibrosis, lung endothelial, and epithelial cell injury. The further delineation of the signaling network that maintains states of lung health and disease will propel the discovery of highly targeted and efficacious approaches against the ferocious outcomes of respiratory dysfunction, including COVID-19.

pharmaceuticals

IMPACT FACTOR 4.6 | Indexed in: PubMed | CITESCORE 4.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande,Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com